Akanda (AKAN) Competitors $1.41 +0.05 (+3.68%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestTrends AKAN vs. ENSC, OBSV, CDT, CERO, SNGX, COEP, NLSP, EVOK, EYEN, and GRIShould you be buying Akanda stock or one of its competitors? The main competitors of Akanda include Ensysce Biosciences (ENSC), ObsEva (OBSV), Conduit Pharmaceuticals (CDT), CERo Therapeutics (CERO), Soligenix (SNGX), Coeptis Therapeutics (COEP), NLS Pharmaceutics (NLSP), Evoke Pharma (EVOK), Eyenovia (EYEN), and GRI Bio (GRI). These companies are all part of the "pharmaceutical products" industry. Akanda vs. Ensysce Biosciences ObsEva Conduit Pharmaceuticals CERo Therapeutics Soligenix Coeptis Therapeutics NLS Pharmaceutics Evoke Pharma Eyenovia GRI Bio Ensysce Biosciences (NASDAQ:ENSC) and Akanda (NASDAQ:AKAN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, risk, valuation, community ranking and earnings. Does the MarketBeat Community believe in ENSC or AKAN? Ensysce Biosciences received 3 more outperform votes than Akanda when rated by MarketBeat users. CompanyUnderperformOutperformEnsysce BiosciencesOutperform Votes360.00% Underperform Votes240.00% AkandaN/AN/A Does the media favor ENSC or AKAN? In the previous week, Ensysce Biosciences had 4 more articles in the media than Akanda. MarketBeat recorded 5 mentions for Ensysce Biosciences and 1 mentions for Akanda. Akanda's average media sentiment score of 0.98 beat Ensysce Biosciences' score of 0.00 indicating that Akanda is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ensysce Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Akanda 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, ENSC or AKAN? Ensysce Biosciences has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500. Comparatively, Akanda has a beta of 1.69, meaning that its share price is 69% more volatile than the S&P 500. Do institutionals and insiders have more ownership in ENSC or AKAN? 5.6% of Ensysce Biosciences shares are held by institutional investors. Comparatively, 1.0% of Akanda shares are held by institutional investors. 7.9% of Ensysce Biosciences shares are held by company insiders. Comparatively, 20.4% of Akanda shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Is ENSC or AKAN more profitable? Akanda has a net margin of 0.00% compared to Ensysce Biosciences' net margin of -179.26%. Akanda's return on equity of 0.00% beat Ensysce Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Ensysce Biosciences-179.26% -292.81% -158.83% Akanda N/A N/A N/A Which has stronger earnings and valuation, ENSC or AKAN? Ensysce Biosciences has higher earnings, but lower revenue than Akanda. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEnsysce Biosciences$2.23M4.74-$10.61M-$27.44-0.30Akanda$2.51M0.80-$32.28MN/AN/A SummaryAkanda beats Ensysce Biosciences on 7 of the 12 factors compared between the two stocks. Ad ProsperityPubThis Indicator called BOTH NVDA ralliesRarely would I label something as “the best” But in this rare instance, I believe this is THE BEST indicator for trading Nvida’s stock. Except, it’s not another tech stock like Nvidia. But rather a stock hiding in broad daylight… So, if you’d like to see what this stock is… Click this link here. Get Akanda News Delivered to You Automatically Sign up to receive the latest news and ratings for AKAN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AKAN vs. The Competition Export to ExcelMetricAkandaMedicinals & botanicals IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.01M$378.07M$5.14B$9.08BDividend YieldN/AN/A5.09%4.23%P/E RatioN/A32.5990.0517.20Price / Sales0.806.081,117.09117.04Price / CashN/A10.6643.1037.85Price / Book-0.021.884.784.78Net Income-$32.28M-$50.37M$120.31M$225.60M7 Day Performance-5.37%-3.56%-1.92%-1.23%1 Month Performance3.68%-7.06%13.65%0.46%1 Year Performance-95.90%-8.73%28.34%15.24% Akanda Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AKANAkandaN/A$1.41+3.7%N/A-95.9%$2.01M$2.51M0.00110ENSCEnsysce Biosciences0.0873 of 5 stars$6.14+9.3%N/A-49.1%$8.02M$2.23M-0.2010OBSVObsEvaN/AN/AN/AN/A$7.94M$20.11M-0.1150Analyst ForecastNews CoverageCDTConduit PharmaceuticalsN/A$0.08-5.5%N/A-98.5%$7.92MN/A0.003CEROCERo TherapeuticsN/A$0.05-8.3%N/AN/A$7.82MN/A0.008SNGXSoligenix0.7346 of 5 stars$3.09-2.2%N/A-69.6%$7.76M$840,000.00-0.4220Positive NewsGap UpCOEPCoeptis Therapeutics0.3751 of 5 stars$0.19+5.3%N/A-83.9%$7.70M$80,000.00-0.612Gap DownNLSPNLS Pharmaceutics0.364 of 5 stars$1.89-1.0%N/A+336.9%$7.21MN/A0.006News CoverageGap UpEVOKEvoke Pharma0.0363 of 5 stars$4.73+0.4%N/A-63.3%$7.05M$5.18M-0.434News CoverageEYENEyenovia1.4856 of 5 stars$0.08-2.4%$2.00+2,354.0%-94.9%$7.05M$31,832.00-0.1140Gap DownHigh Trading VolumeGRIGRI Bio2.5218 of 5 stars0.78-2.9%N/A-97.8%$6.94MN/A0.001 Related Companies and Tools Related Companies ENSC Competitors OBSV Competitors CDT Competitors CERO Competitors SNGX Competitors COEP Competitors NLSP Competitors EVOK Competitors EYEN Competitors GRI Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AKAN) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredMUST SEE: The most important video in the world right now?If you have a significant amount of money in the stock market right now — or if you're sitting on the sideline...InvestorPlace | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akanda Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akanda With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
